Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/025—Enterobacteriales, e.g. Enterobacter
  • A61K39/0275—Salmonella
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55516—Proteins; Peptides
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates in general to the dendritic cell (DC)-targeting vaccines, and more particularly, to the enhancing vaccine efficacy by directly linking adjuvants (e.g., TLR ligands) directly to DC-targeting vaccines.
• adjuvants e.g., TLR ligands
• DC dendritic cell
• U.S. Patent Application Publication No. 20090004194 (Kedl, 2007) relates to novel protein and DNA conjugates which promote antigen specific cellular immunity.
• the Kedl invention discloses fusion proteins and DNA conjugates containing a TLR/CD40/agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases is also taught.
• U.S. Patent Application Publication No. 20080220011 provides a fusion protein comprising a flagellin adjuvant and a tumor antigen. Also provided are compositions comprising a flagellin adjuvant and a tumor antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against a tumor antigen and methods of treating a tumor in a subject.
• U.S. Patent Application Publication No. 20080248068 (Ljunggren et al. 2008) is directed to flagellin and its use as an adjuvant for vaccination.
• the invention can be used in vaccine formulations to improve immunity against any other antigen administered at the same localization.
• the antigen can be administered in the same construct as Flagellin or in any other formulation given at the same localization.
• flagellin can be used to stimulate immunity against antigens expressed at a specific location.
• Flagellin can also be used to induce local inflammation with the purpose of creating a model for inflammation.
• flagellin is capable of inhibiting tolerance when it is administered in conjunction with a tolerogenic antigen. This effect is likely mediated by the ability of flagellin to induce IL-12 while keeping IL-10 levels low.
• flagellin can be provided in an extended-releasing manner by using a flagellin-expressing cell. Preferably, the flagellin-expressing cell is treated such that it is no longer capable of replicating, yet retaining the ability to express flagellin, such as by lethal irradiation.
• the present invention describes compositions and methods for making novel vaccine adjuvants based on targeting adjuvants with antibodies directly to antigen-presenting cells.
• the present invention was found to enhance vaccine efficacy by linking adjuvants (e.g., TLR ligands) directly to DC -targeting vaccines.
• adjuvants e.g., TLR ligands
• the compositions and methods of the present invention are broadly applicable to all DC-targeting vaccines and extensible to making adjuvants with unexpected novel properties.
• the present invention in one embodiment discloses an adjuvant composition
• an adjuvant composition comprising an anti- dendritic cell (DC)-specific antibody or binding fragment thereof conjugated to a TLR agonist; and at least one antigen, wherein the antigen and the agonist are effective to produce an immune response in a human or animal subject in need of immunostimulation.
• DC dendritic cell
• the DC-specific antibody or fragment described hereinabove is selected from an anti-DCIR, MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CDl lb, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN- ⁇ receptor and IL-2 receptor, ICAM-1, Fey receptor, LOX-1, or ASPGR.
• the composition described above further comprises antigenic peptides selected from human immunodeficiency virus (HIV) antigens and gene products selected from the group consisting of gag, pol, and env genes, the Nef protein, reverse transcriptase, string of HIV peptides (Hipo5), PSA (KLQCVDLHV)-tetramer, a HIVgag-derived p24-PLA HIV gag p24 (gag), and other HIV components, hepatitis viral antigens, influenza viral antigens and peptides selected from the group consisting of hemagglutinin, neuraminidase, Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, and Avian Flu (HA5- 1), dockerin domain from C.
• HV human immunodeficiency virus
• gene products selected from the group consisting of gag
• composition further comprises antigenic peptides selected from one or more bacterial antigens, wherein the bacterial antigens comprise antigens derived from Bacillus, Escherichia, Listeria, Neisseria, Nocardia, Salmonella, Staphylococcus, Streptococcus, or combinations and modifications thereof.
• composition further comprises antigenic peptides selected from cancer peptides selected from tumor associated antigens comprising antigens from leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia.
• neurological tumors such as
• the tumor associated antigens are selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin B 1 , cyclin D, Pmel 17(gp 100), GnT- V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), ⁇ -catenin, MUM-l-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10, c- ERB2 (Her2/neu).
• DC-specific antibody is humanized.
• the TLR agonist comprises at least one of a flagellin from Salmonella enterica, a flagellin from Vibrio cholerae, any other TLR5 agonist, a TLR7 agonist, a TLR9 agonist, or any combinations or modifications thereof.
• the antigen is conjugated to the antibody and TLR agonist.
• the antigen and the antibody are a single fusion protein.
• the antibody comprises at least one of a light chain, a heavy chain, or a heavy and a light chain.
• the present invention in another embodiment provides a vaccine composition
• a vaccine composition comprising: (i) an antigen and (ii) an adjuvant, wherein the adjuvant comprises an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist in an amount effective to produce an immune response in a human or animal subject in need of immunostimulation.
• DC anti-dendritic cell
• the DC- specific antibody or fragment used in the vaccine hereinabove is selected from an anti-DCIR, MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CDl lb, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN- ⁇ receptor and IL-2 receptor, ICAM-1, Fey receptor, LOX-1, or ASPGR.
• the vaccine composition further comprises antigenic peptides selected.
• antigenic peptides selected from one or more bacterial antigens. A list of non-limiting bacterial antigens has been previously described hereinabove.
• the vaccine further comprises antigenic peptides selected from cancer peptides selected from tumor associated antigens comprising antigens that have been previously described.
• composition further comprises antigenic peptides selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin Bl, cyclin D, Pmel 17(gpl00), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), ⁇ -catenin, MUM-l-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10,
• MUC
• the DC-specific antibody is humanized.
• the TLR agonist comprises at least one of a flagellin from Salmonella enterica, a flagellin from Vibrio cholerae, any other TLR5 agonist, a TLR7 agonist, a TLR9 agonist, or any combinations or modifications thereof.
• the antigen is conjugated to the antibody and TLR agonist.
• the antigen and the antibody are a single fusion protein.
• the antibody comprises at least one of a light chain, a heavy chain, or a heavy and a light chain.
• the instant invention discloses a method for increasing effectiveness of antigen presentation by an antigen presenting cell comprising: contacting the antigen presenting cell with a composition comprising: (i) an antigen; and (ii) an adjuvant, wherein the adjuvant comprises an anti-dendritic cell (DC)-specific antibody or binding fragment thereof conjugated to a TLR agonist, wherein the antigen and adjuvant are provided in an amount effective to produce an immune response in a human or animal subject in need of immunostimulation.
• DC anti-dendritic cell
• the DC-specific antibody or fragment is selected from an anti-DCIR, MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CDl lb, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN- ⁇ receptor and IL-2 receptor, ICAM-1, Fey receptor, LOX-1, or ASPGR.
• an anti-DCIR MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CDl lb, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56
• the anti -DC-specific antibody is selected from pairs of SEQ ID NOS.: 7 and 9, 11 and 13, 15 and 17, 19 and 21, 23 and 25, 27 and 29, 31 and 33, 35 and 37, 39 and 41, 43 and 45, 47 and 49, 51 and 53, 55 and 57, 59 and 61, 63 and 65, 67 and 69, 71 and 73, 75 and 77, 79 and 81, 83 and 85, 87 and 89, 91 and 93, 95 and 97, 99 and 101, 1-3 and 105, 107 and 109, 111 and 113, 115 and 117, 119 and 121, 123 and 125, 127 and 129, 131 and 132, 133 and 134.
• composition further comprises antigenic peptides, non-limiting examples of the antigenic peptides have been described previously.
• composition further comprises antigenic peptides selected from cancer peptides as previously described.
• the antigenic peptides are selected from tumor associated antigens. Non-limiting examples of tumor associated antigens are described hereinabove.
• the DC-specific antibody is humanized and the composition is administered to the human or animal subject by an oral route, a nasal route, topically or as an injection (the injection is selected from intradermal, intramucosal, subcutaneous, intravenous, intraperitoneal, intramuscular, and intravenous injections).
• the TLR agonist comprises at least one of a flagellin from Salmonella enterica, a flagellin from Vibrio cholerae, any other TLR5 agonist, a TLR7 agonist, a TLR9 agonist, or any combinations or modifications thereof.
• the antigen is conjugated to the antibody and TLR agonist.
• the antigen and the antibody are a single fusion protein.
• the antibody comprises at least one of a light chain, a heavy chain, or a heavy and a light chain.
• the present invention further provides a method for a treatment, a prophylaxis or a combination thereof against one or more cancers in a human subject comprising the steps of: (i) identifying the human subject in need of the treatment, the prophylaxis or a combination thereof against the one or more cancers and (ii) administering a vaccine composition comprising: a) an antigen and b) an adjuvant, wherein the adjuvant comprises an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to a TLR agonist; and a pharmaceutically acceptable carrier, wherein the antigen and adjuvant are provided in an amount effective to produce an immune response for the treatment, the prophylaxis or a combination thereof against the one or more cancers.
• a vaccine composition comprising: a) an antigen and b) an adjuvant, wherein the adjuvant comprises an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to a TLR agonist; and a pharmaceutically acceptable carrier,
• Another embodiment of the present invention relates to a method of providing immunostimulation by activation of one or more dendritic cells (DCs) to a human subject for a prophylaxis, a therapy or a combination thereof against one or more viral, bacterial, fungal, parasitic, protozoal, and parasitic diseases, and allergic disorders comprising the steps of: i) identifying the human subject in need of immunostimulation for the prophylaxis, the therapy or a combination thereof against the one or more viral, bacterial, fungal, parasitic, protozoal, and parasitic diseases, and allergic disorders; ii) isolating one or more DCs from the human subject; iii) activating the isolated DCs with an amount of a composition effective for forming activated DCs comprising: a) an antigen and b) an adjuvant, wherein the adjuvant comprises an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to a TLR agonist; and a pharmaceutically acceptable carrier,
• the instant invention discloses an adjuvant composition
• an adjuvant composition comprising an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist wherein the anti-DC-specific antibody is selected from pairs of SEQ ID NOS.: 7 and 9, 11 and 13, 15 and 17, 19 and 21, 23 and 25, 27 and 29, 31 and 33, 35 and 37, 39 and 41, 43 and 45, 47 and 49, 51 and 53, 55 and 57, 59 and 61, 63 and 65, 67 and 69, 71 and 73, 75 and 77, 79 and 81, 83 and 85, 87 and 89, 91 and 93, 95 and 97, 99 and 101, 1-3 and 105, 107 and 109, 111 and 113, 115 and 117, 119 and 121, 123 and 125, 127 and 129, 131 and 132, 133 and 134.
• DC dendritic cell
• the composition further comprises antigenic peptides selected from human immunodeficiency virus (HIV) antigens and gene products selected from the group consisting of gag, pol, and env genes, the Nef protein, reverse transcriptase, string of HIV peptides (Hipo5), PSA (KLQCVDLHV)-tetramer, a HIVgag-derived p24-PLA HIV gag p24 (gag), and other HIV components, hepatitis viral antigens, influenza viral antigens and peptides selected from the group consisting of hemagglutinin, neuraminidase, Influenza A Hemagglutinin HA- 1 from a H1N1 Flu strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, and Avian Flu (HA5-1), dockerin domain from C.
• HV human immunodeficiency virus
• gene products selected from the group consisting of gag,
• thermocellum measles viral antigens, rubella viral antigens, rotaviral antigens, cytomegaloviral antigens, respiratory syncytial viral antigens, herpes simplex viral antigens, varicella zoster viral antigens, Japanese encephalitis viral antigens, rabies viral antigens or combinations and modifications thereof.
• composition further comprises antigenic peptides selected from cancer peptides selected from tumor associated antigens comprising antigens from leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non- Hodgkin's lymphoma, multiple myeloma and leukemia.
• neurological tumors such as
• composition further comprises antigenic peptides selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC- 1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin Bl, cyclin D, Pmel 17(gpl00), GnT-V intron V sequence (N- acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), ⁇ -catenin, MUM-l-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10,
• MUC
• the DC-specific antibody is humanized.
• the TLR agonist comprises at least one of a flagellin from Salmonella enterica, a flagellin from Vibrio cholerae, any other TLR5 agonist, a TLR7 agonist, a TLR9 agonist, or any combinations or modifications thereof and the antigen and the antibody are a single fusion protein.
• the antibody comprises at least one of a light chain, a heavy chain, or a heavy and a light chain.
• FIGS. 1A-1D show flagellin and the several antibody-flagellin constructs of the present invention: FIG. 1A Residues from the conserved N-terminal and C-terminal regions are together sufficient to activate TLR5 - central residues are expendable for this function, FIG. IB An example of a active configuration of flagellin fused directly to a DC -targeting antibody to direct the activation properties of the flagellin fragment specifically to cells expressing the particular DC receptor and combining immunostimulatory properties of the flagellin with those of the anti-DC receptor antibody, FIG. 1C A variant of IB wherein fragments of the two conserved flagellin domains are separated by a linker or antigen sequence - in the example given in FIG.
• Figs 3 and 4 show examples of immune stimulation by such a variant.
• FIG. 2 shows the design of the studies used to test the activity of the antibody-flagellin constructs of the present invention
• FIGS. 3A to 3C show the secretion of IL-6 when various types of cells were activated with the constructs of the present invention
• FIGS. 4A to 4D show the dose titration of the various constructs as measured by the secretion of IL-6 and IL-1 beta.
• the data demonstrate that the immune stimulation by the flagellin fragments becomes dependent upon DC receptor interaction (in this case LOX-1) mediated by the DC -targeting antibody portion of the construct - a control hIgG4-flagellin construct is only active at much higher concentrations.
• Other controls show that it is the direct fusion of the flagellin fragments to the DC- targeting antibody that accounts for the enhanced immunostimulatory potency; and
• FIG. 5 shows heat maps of gene expression for the listed genes using an anti-LOX-1 antibody with or without linked flagellin.
• the exact combination of up-regulated immune stimulatory molecules will vary with different anti-DC receptor antibody constructs linked to the flagellin fragment because different combinations of target cells will be engaged and there will be different combinations of signaling via the flagellin and the DC-targeting antibody.
• Antigen Presenting Cells are cells that are capable of activating T cells, and include, but are not limited to, certain macrophages, B cells and dendritic cells.
• DCs dendritic cells
• DCs refers to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression (Steinman, et al., Ann. Rev. Immunol. 9:271 (1991); incorporated herein by reference for its description of such cells). These cells can be isolated from a number of tissue sources, and conveniently, from peripheral blood, as described herein.
• Dendritic cell binding proteins refers to any protein for which receptors are expressed on a dendritic cell. Examples include GM-CSF, IL-1, TNF, IL-4, CD40L, CTLA4, CD28, and FLT-3 ligand.
• the term "vaccine composition” is intended to mean a composition which can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in a production of antibodies or simply in the activation of certain cells, in particular antigen-presenting cells, T lymphocytes and B lymphocytes.
• the vaccine composition can be a composition for prophylactic purposes or for therapeutic purposes, or both.
• the term “antigen” refers to any antigen that can be used in a vaccine, whether it involves a whole microorganism or a portion thereof, and various types : (e.g., peptide, protein, glycoprotein, polysaccharide, glycolipid, lipopeptide, etc).
• the term "antigen" also comprises the polynucleotides, the sequences of which are chosen so as to encode the antigens whose expression by the individuals to which the polynucleotides are administered is desired, in the case of the immunization technique referred to as DNA immunization.
• They may also be a set of antigens, in particular in the case of a multivalent vaccine composition which comprises antigens capable of protecting against several diseases, and which is then generally referred to as a vaccine combination, or in the case of a composition which comprises several different antigens in order to protect against a single disease, as is the case for certain vaccines against whooping cough or the flu, for example.
• antibodies refers to immunoglobulins, whether natural or partially or wholly produced artificially, e.g. recombinant.
• An antibody may be monoclonal or polyclonal.
• the antibody may, in some cases, be a member of one, or a combination immunoglobulin classes, including: IgG, IgM, IgA, IgD, and IgE.
• adjuvant or “immunoadjuvant” may be used interchangeably and refer to a substance that enhances, augments or potentiates the host's immune response to an antigen, e.g., an antigen that is part of a vaccine.
• antigen e.g., an antigen that is part of a vaccine.
• Non-limiting examples of some commonly used vaccine adjuvants include insoluble aluminum compounds, calcium phosphate, liposomes, VirosomesTM, ISCOMS®, microparticles (e.g., PLG), emulsions (e.g., MF59, Montanides), virus-like particles & viral vectors.
• Flagellin a TLR5 agonist from Salmonella entericum is used as an adjuvant in the present invention.
• flagellin from other bacterial sources may also be used, other TLR5 agonists, TLR7 agonists, TLR9 agonists, or any combinations or modifications thereof may also be used.
• conjugate refers to any substance formed from the joining together of two parts.
• Representative conjugates in accordance with the present invention include those formed by joining together of the antigen with the antibody and the TLR agonist.
• conjugation refers to the process of forming the conjugate and is usually done by physical coupling, e.g. covalent binding, co-ordination covalent, or secondary binding forces, e.g. Van der Waals bonding forces.
• the process of linking the antigen to the antibody and the TLR agonist can also be done via a non- covalent association such as a dockerin-cohesin association (as described in U.S. Patent Publication No. 20100135994, Banchereau et al. relevant portions incorporated herein by reference) or by a direct chemical linkage by forming a peptide or chemical bond.
• flagellin refers to a flagellin protein from any source including, but not limited to, any bacterial species.
• the flagellin may be from a species of Salmonella (Salmonella enterica as exemplified herein) or from other species of bacteria (for e.g. Vibrio cholerae). Also specifically contemplated are fragments, variants, analogs, homologs, or derivatives of said flagellin, and combinations thereof.
• the various fragments, variants, analogs, homologs or derivatives described herein may be 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to a wild-type flagellin from a specific bacterial species, e.g., Salmonella.
• gene is used to refer to a functional protein, polypeptide or peptide-encoding unit. As will be understood by those in the art, this functional term includes genomic sequences, cDNA sequences, or fragments or combinations thereof, as well as gene products, including those that may have been altered by the hand of man. Purified genes, nucleic acids, protein and the like are used to refer to these entities when identified and separated from at least one contaminating nucleic acid or protein with which it is ordinarily associated
• nucleic acid or “nucleic acid molecule” refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action.
• DNA deoxyribonucleic acid
• RNA ribonucleic acid
• PCR polymerase chain reaction
• Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., a-enantiomeric forms of naturally-occurring nucleotides), or a combination of both.
• Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties.
• Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
• the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
• modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes.
• Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like.
• nucleic acid molecule also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a poly amide backbone. Nucleic acids can be either single stranded or double stranded.
• amino acid means one of the naturally occurring amino carboxylic acids of which proteins are comprised.
• polypeptide as described herein refers to a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides.”
• a “protein” is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
• the term “in vivo” refers to being inside the body.
• the term “in vitro” used as used in the present application is to be understood as indicating an operation carried out in a non-living system.
• the term “treatment “ or “treating” means any administration of a compound of the present invention and includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology) .
• the present invention describes novel vaccine adjuvants based on targeting adjuvants with antibodies directly to antigen-presenting cells.
• the present invention was found to enhance vaccine efficacy by directly linking adjuvants (e.g., TLR ligands) directly to DC -targeting vaccines.
• adjuvants e.g., TLR ligands
• the compositions and methods of the present invention are broadly applicable to all DC -targeting vaccines and extensible to making adjuvants with unexpected novel properties.
• antigens directly linked to adjuvants e.g., TLR's
• the present invention is an adjuvant that is directly linked to a DC-targeting vaccine (e.g., anti-DC receptor antibody fused to antigen).
• a DC-targeting vaccine e.g., anti-DC receptor antibody fused to antigen.
• compositions and methods described herein can be used in a prophylaxis, a therapy or a combination thereof against one or more viral, bacterial, fungal, parasitic, protozoal, and parasitic diseases, allergic disorders, and cancers.
• diseases against which a prophylaxis, a therapy, alleviation of symptoms or combinations thereof can be achieved using the composition of the present invention include HIV infections, hepatitis, influenza, avian flu, herpes, genitourinary, prostate, and neurological tumors, arthritis, asthma, eczema, bacterial infections selected from anthrax, cholecystitis, bacteremia, cholangitis, urinary tract infection (UTI), listeriosis, meningococcal infections, salmonellosis, necrotizing fasciitis and streptococcal toxic shock syndrome, pneumonia, skin infections, or any combinations or modifications thereof.
• HIV infections hepatitis, influenza, avian flu, herpes, genitourinary, prostate, and neurological
• Flagellin from Salmonella enterica has been exemplified in the present invention. However, a skilled artisan will understand that flagellin from many bacterial species (for e.g., Vibrio cholerae) can be substituted for the flagellin that is used herein. In addition to flagellin other TLR5 agonists may also be used. For extending the invention to other TLRs, it may be necessary to employ chemical linkages since some or all of the other known TLR ligands are non-protein. Some agonists like TLR7 and TLR9, are well described chemical entities and methods to link them to proteins, while maintaining their intrinsic TLR agonistic properties, have benne previously described.
• compositions and method described hereinabove use TLR agonists conjugated an anti-dendritic cell (DC)-specific antibody or binding fragment thereof.
• DC anti-dendritic cell
• a skilled artisan will recognize that other non-TLR based ligands, agonists, or other moieties (for e.g. infammasome) may be conjugated to the antibody to achieve the desired in vivo or ex vivo effects.
• composition comprising the antigen-TLR agonist- antibody
• the TLR agonist may be linked to the heavy chain (ANTIBODY L CHAIN-ANTIGEN+H CHAIN-TLR AGONIST or the light-chain (ANTIBODY H CHAIN-ANTIGEN+ L CHAIN- TLR AGONIST or ANTIBODY H CHAIN-ANTIGEN- TLR AGONIST +L CHAIN) of the anti-dendritic cell (DC)-specific antibody.
• the conjugate may also be prepared by linking the TLR agonist/flagellin through a dockerin-cohesin attachment (for e.g.
• flagellin used herein may be substituted or replaced by any TLR agonist that may be linked by similar chemical or physical methods.
• the present invention may also include the combination wherein the antigen and the antibody are a single fusion protein.
• DC-targeting linked adjuvant attachment A (SEQ ID NO: 1): Vector C959 encodes rAB- pIRES2 [mAnti-DCIR_9E8_H-LV-hIgG4H-C-Flex-v 1 -Flgn- 1 -Flgn-2] .
• phase-2 flagellin [Salmonella enterica] gb
• phase-2 flagellin [Salmonella enterica] gb
• Italics is a flexible linker sequence from gb
• the amino terminus up to the first AS sequence is the heavy chain of mouse Anti-DCIR_9E8 variable region fused to -hIgG4H constant region.
• AS sequences in bold-italics are joining sequences from construction of the expression vector.
• this vector When co-transfected with appropriate L chain expression vector into mammalian cells (e.g., CHO-S cells) this vector directs efficient secretion of a typical embodiment of a DC-targeting agent linked to a flagellin-based adjuvant.
• mammalian cells e.g., CHO-S cells
• C1099 encodes mouse Anti-DCIR_9E8_H-LV-hIgG4H-C-Dockerin-v2-Flgn-l-Flgn-2] (SEQ ID NO: 2).
• phase-2 flagellin [Salmonella enterica] gb
• phase-2 flagellin [Salmonella enterica] gb
• this vector When co-transfected with appropriate L chain expression vector into mammalian cells (e.g., CHO-S cells) this vector directs efficient secretion of a typical embodiment of a DC-targeting agent linked to a flagellin-based adjuvant and linked to cohesin-antigen via the dockerin domain.
• a DC-targeting agent linked to a flagellin-based adjuvant and linked to cohesin-antigen via the dockerin domain.
• any desired antigen can also be directly fused in place of the dockerin domain.
• Bold is the cohesin domain showing an underlined single C to A change that maintains dockerin binding and 3 C residues (bold-underlined) that permit site-specific maleimide linkage of TLRL adducts.
• Underlined is the Flu Ml antigen sequence. AS sequences in bold-italics are joining sequences from construction of the expression vector.
• any cohesin-antigen with free cys residues can vbe conveniently decorated with TLR7-L compound and linked with any anti-DC receptor-dockerin-antigen vaccine.
• C1450 encodes mouse Anti-DCIR_9E8_H-LV-hIgG4H-C-Flex-vl-vlC2 (SEQ ID NO: 4):
• Bold is a flexible linker sequence bearing two C residues (underlined) for site-specific linking TLRL adducts.
• mammalian cells e.g., CHO-S cells
• this vector directs efficient secretion of a typical embodiment of a DC -targeting agent linked to a chemical-based adjuvant.
• - other vectors can be prepared with any desired antigen directly fused to the C-terminal codon.
• AS sequences in bold-italics are joining sequences from construction of the expression vector. Italics is a flexible linker (supra).
• CI 180 directs the expression of a mammalian cell expressed 6xHis-Cohesin-Flgn-l-Flgn-2 fusion protein (SEQ ID NO: 5):
• Anti_CLEC_6_9B9.2G12_Hv-V-hIgG4H-C (SEQ ID NO: 6):
• Anti_CLEC_6_9B9.2G12_Hv-V-hIgG4H-C (SEQ ID NO: 7):
• Anti_CLEC_6_9B9.2G12_Kv-V-hIgGK-C (SEQ ID NO: 8):
• Anti_CLEC_6_9B9.2G12_Kv-V-hIgGK-C (SEQ ID NO: 9):
• Anti-ASGPR_49C11 7H-LV-hIgG4H-C (SEQ ID NO: 10):
• Anti-ASGPR_49C11 7H-LV-hIgG4H-C (SEQ ID NO: 11):
• Anti-ASGPR_49C1 l_7K-LV-hIgGK-C (SEQ ID NO: 12):
• Anti-ASGPR_49Cl l_7K-LV-hIgGK-C (SEQ ID NO: 13):
• Anti-ASGPR_4G2.2_Hv-V-hIgG4H-C (SEQ ID NO: 14):
• Anti-ASGPR_4G2.2_Hv-V-hIgG4H-C (SEQ ID NO: 15):
• Anti-ASGPR_4G2.2_Kv-V-hIgGK-C SEQ ID NO: 16:
• Anti-ASGPR_4G2.2_Kv-V-hIgGK-C SEQ ID NO: 17:
• Anti-ASGPR_5F10H-LV-hIgG4H-C (SEQ ID NO: 18):
• Anti-ASGPR_5F10H-LV-hIgG4H-C (SEQ ID NO: 19):
• Anti-ASGPR_5F 1 OK-LV-hlgGK-C (SEQ ID NO: 20):
• Anti-ASGPR_5F 1 OK-LV-hlgGK-C (SEQ ID NO: 21):
• Anti-ASGPRIHI l_H-V-hIgG4H-C (SEQ ID NO: 22):
• Anti-ASGPRIHI l_H-V-hIgG4H-C (SEQ ID NO: 23):
• Anti-ASGPRIHI lK-LV-var2-hIgGK-C (SEQ ID NO: 24):
• Anti-ASGPRIHI lK-LV-var2-hIgGK-C (SEQ ID NO: 25):
• Anti-CDld_2B5.3G10_K-V-hIgGK-C (SEQ ID NO: 28):
• Anti-CDld_2B5.3G10_K-V-hIgGK-C (SEQ ID NO: 29):
• Anti-CD ld_2H11.2G5_K-V-hIgGK-C (SEQ ID NO: 32):
• Anti-CD ld_2H11.2G5_K-V-hIgGK-C (SEQ ID NO: 33):
• Anti-CD40_1 lB6.1C3_H-LV-hIgG4H-C (SEQ ID NO: 34):
• Anti-CD40_l lB6.1C3_H-LV-hIgG4H-C (SEQ ID NO: 35):
• Anti-CD40_l lB6.1C3_K-LV-hIgGK-C (SEQ ID NO: 36): ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATG TTGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTC TTGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGAAACACCTATTTACATTGGTACCT GCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGG GGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCGCACTCAAGATCAGTA GAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCTCTCTCAAAGTACACATGTTCCGTGGA CGTTCGGTGGAGGCACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCA TCTTCCCGCCATCTGAT
• Anti-CD40_l lB6.1C3_K-LV-hIgGK-C (SEQ ID NO: 37):
• Anti-CD40_12B4.2C10_H-LV-hIgG4H-C (SEQ ID NO: 38):
• Anti-CD40_12B4.2C10_H-LV-hIgG4H-C (SEQ ID NO: 39):
• Anti-CD40_12B4.2C10_K-LV-v2-hIgGK-C (SEQ ID NO: 40):
• Anti-CD40_12B4.2C10_K-LV-v2-hIgGK-C (SEQ ID NO: 41):
• Anti-CD40_12E12.3F3_H-V-hIgG4H-C (SEQ ID NO: 43):
• Anti-CD40_12E12.3F3_K-LV-hIgGK-C (SEQ ID NO: 44): ATGATGTCCTCTGCTCAGTTCCTTGGTCTCCTGTTGCTCTGTTTTCAAGGTACCAGATGTG ATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTAGGAGACAGAGTCACCA TCAGTTGCAGTGCAAGTCAGGGCATTAGCAATTATTTAAACTGGTATCAGCAGAAACCA GATGGAACTGTTAAACTCCTGATCTATTACACATCAATTTTACACTCAGGAGTCCCATCA AGGTTCAGTGGCAGTGGGTCTGGGACAGATTATTCTCTCACCATCGGCAACCTGGAACCT GAAGATATTGCCACTTACTATTGTCAGCAGTTTAATAAGCTTCCTCCGACGTTCGGTGGA GGCACCAAACTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA TCTGATGAAATCTGTCTTCATCTTCCCGCCA
• Anti-CD40_12E12.3F3_K-LV-hIgGK-C (SEQ ID NO: 45):
• Anti-DCIR_24A5.4A5_H-V-hIgG4H-C (SEQ ID NO: 46):
• Anti-DCIR_24A5.4A5_H-V-hIgG4H-C (SEQ ID NO: 47):
• Anti-DCIR_24A5.4A5_K-V-hIgGK-C (SEQ ID NO: 48):
• Anti-DCIR_24A5.4A5_K-V-hIgGK-C (SEQ ID NO: 49):
• Anti-DCIR_24E7.3H9_H-V-hIgG4H-C (SEQ ID NO: 51):
• Anti-DCIR_24E7.3H9_K-V-hIgGK-C (SEQ ID NO: 52): ATGACCATGTTCTCACTAGCTCTTCTCCTCAGTCTTCTTCTCCTCTGTGTCTCTGATTCTAG GGCAGAAACAACTGTGACCCAGTCTATGACCATGTTCTCACTAGCTCTTCTCCTCAGTCTT CTTCTCCTCTGTGTCTCTGATTCTAGGGCAGAAACAACTGTGACCCAGTCTCCAGCATCCC TGTCCATGGCTATAGGGGAAAAAGTCACCATCAGATGCGTAACCAGCACTGATATTGAT GATGATGTGAACTGGTACCAGCAGAAGCCAGGGGAACCTCCTAAACTCCTTATTTCAGA AGGCAATACTCTTCGTCCTGGAGTCCCATCCCGATTCTCCAGCAGTGGCTATGGTACAGA TTGTTTACAATTGAAACATGCTCAGAAGATGTTGCAGATTACTACTGTTTGCAA AGTGGTAACTTGCCGTACACGTTCGGAGGGGGGACCAAGCTCAGAA
• Anti-DCIR_24E7.3H9_K-V-hIgGK-C (SEQ ID NO: 53):
• Anti-DCIR_29E9.2E2_H-VhIgG4H-C (SEQ ID NO: 54):
• Anti-DCIR_29E9.2E2_H-VhIgG4H-C (SEQ ID NO: 55):
• Anti-DCIR_29E9.2E2_K-V-hIgGK-C (SEQ ID NO: 56):
• Anti-DCIR_29E9.2E2_K-V-hIgGK-C (SEQ ID NO: 57):
• Anti-DCIR_29G10.3D9_H-V-hIgG4H-C (SEQ ID NO: 58):
• Anti-DCIR_29G10.3D9_H-V-hIgG4H-C (SEQ ID NO: 59):
• Anti-DCIR_29G10.3D9_K-Varl-V-hIgGK-C (SEQ ID NO: 60): ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATGAGTGCCTCAGTCATAATGTCCA GGGGACAAATTGTTCACCCAGTCTCCAGCACTCATGTCTGCATCTCCAGGGGAGAAGG TCACCATGACCTGCAGTGCCAGCTCAAATATAAGTTACATGTACTGGTACCAGCAGAAGC CAAGATCCTCCCAAACCCTGGATTTATCTCACATCCAACCTGGCTTCTGGAGTCCCTG CTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAACCAGCAGCATGGAGG CTGAAGATGCTGCCACTTATTGCTGCCAGCAGTGGAGTAGTAACCCACCCACGTTCGGTG CTGGGACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGC CATCTGATGAGCAGTTCATCTTCCCGC CA
• Anti-DCIR_29G10.3D9_K-Varl-V-hIgGK-C SEQ ID NO: 61:
• Anti-DCIR_29G10.3D9_K-Var2-V-hIgGK-C (SEQ ID NO: 62):
• Anti-DCIR_29G10.3D9_K-Var2-V-hIgGK-C (SEQ ID NO: 63):
• Anti-DCIR_2C9K-V-hIgGK-C (SEQ ID NO: 65):
• Anti-DCIR_31A6.1F5_H-var2-V-hIgG4H-C (SEQ ID NO: 66):
• Anti-DCIR_31A6.1F5_H-var2-V-hIgG4H-C (SEQ ID NO: 67):
• Anti-DCIR_31A6.1F5_K-var2-V-hIgGK-C (SEQ ID NO: 68):
• Anti-DCIR_31A6.1F5_K-var2-V-hIgGK-C (SEQ ID NO: 69):
• Anti-DCIR_3C2.2D9_H-LV-hIgG4H-C (SEQ ID NO: 70):
• Anti-DCIR_3C2.2D9_H-LV-hIgG4H-C (SEQ ID NO: 71):
• Anti-DCIR_3C2.2D9_K-LV-hIgGK-C (SEQ ID NO: 72):
• Anti-DCIR_3C2.2D9_K-LV-hIgGK-C (SEQ ID NO: 73):
• Anti-DCIR_6C8.1G9_H-V-hIgG4H-C (SEQ ID NO: 74):
• Anti-DCIR_6C8.1G9_H-V-hIgG4H-C (SEQ ID NO: 75):
• Anti-DCIR_6C8.1G9_K-V-hIgGK-C (SEQ ID NO: 76):
• Anti-DCIR_6C8.1G9_K-V-hIgGK-C (SEQ ID NO: 77): MTMF SL ALLL SLLLLC VSDSRAETT VTQSPASL SMAIGEKVTIRCVT STDIDDDVN WYQQKPG EPPKLLISEGNTLRAGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSGNLPYTFGGGTKL EIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• Anti-DCIR_9E8.1E3_H-V-hIgG4H-C (SEQ ID NO: 78):
• Anti-DCIR_9E8.1E3_H-V-hIgG4H-C (SEQ ID NO: 79):
• Anti-DCIR_9E8.1E3_K-LV-hIgGK-C (SEQ ID NO: 80):
• Anti-DCIR_9E8.1E3_K-LV-hIgGK-C (SEQ ID NO: 81):
• Anti-DCIR2C9H-LV-hIgG4H-V-hIgG4H-C SEQ ID NO: 82:
• Anti-DCIR2C9H-LV-hIgG4H-V-hIgG4H-C SEQ ID NO: 83:
• Anti-DC-SIGNL 16E3H (SEQ ID NO: 84):
• Anti-DC-SIGNL 16E3H (SEQ ID NO: 85):
• Anti-DC-SIGNL 16E3K (SEQ ID NO: 86):
• Anti-DC-SIGNL 16E7H-LV-hIgG4H-C (SEQ ID NO: 88):
• Anti-DC-SIGNL 16E7H-LV-hIgG4H-C (SEQ ID NO: 89):
• Anti-DC-SIGNLl 6E7K-LV-hIgGK-C SEQ ID NO: 90:
• Anti-DC-SIGNLl 6E7K-LV-hIgGK-C (SEQ ID NO: 91):
• Anti-Dectin_l_l lB6.4_H-V-hIgG4H-C SEQ ID NO: 92:
• Anti-Dectin_l_l lB6.4_H-V-hIgG4H-C SEQ ID NO: 93:
• Anti-Dectin l l lB6.4_K-LV-hIgGK-C SEQ ID NO: 94:
• Anti-Dectin_l_15E2.5_H-V-hIgG4H-C (SEQ ID NO: 96):
• Anti-Dectin_l_15E2.5_H-V-hIgG4H-C (SEQ ID NO: 97):
• Anti-Dectin_l_15E2.5_K-V-hIgGK-C (SEQ ID NO: 98):
• Anti-Dectin_l_15E2.5_K-V-hIgGK-C (SEQ ID NO: 99):
• Anti-Dectin_l_2D8.2D4H-V-hIgG4H-C SEQ ID NO: 100:
• Anti-Dectin_l_2D8.2D4H-V-hIgG4H-C SEQ ID NO: 101:
• Anti-Dectin_l_2D8.2D4K-V-hIgGK-C SEQ ID NO: 102
• Anti-Dectin_l_2D8.2D4K-V-hIgGK-C (SEQ ID NO: 103): DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYAAQSISGIPSRFSGS GSGSDFTLSINGVEPEDVGVYYCQNGHSFPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGT ASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC
• Anti-Langerinl 5B 10H-LV-hIgG4H-C (SEQ ID NO: 104):
• Anti-Langerinl 5B 10H-LV-hIgG4H-C (SEQ ID NO: 105):
• Anti-Langerinl5B10K-LV-hIgGK-C (SEQ ID NO: 106):
• Anti-Langerinl5B10K-LV-hIgGK-C (SEQ ID NO: 107):
• Anti-Langerin2G3H-LV-hIgG4H-C (SEQ ID NO: 108):
• Anti-Langerin2G3H-LV-hIgG4H-C (SEQ ID NO: 109):
• Anti-Langerin2G3L-LV-hIgGK-C (SEQ ID NO: 110):
• Anti-Langerin2G3L-LV-hIgGK-C (SEQ ID NO: 111): MAWI SLIL SLL ALS SGAISQAVVTQE SALTT SPGET VTLTCRS STGAVTT SNYAN WVQEKPDH LFTGLIGGTNNRVSGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKL EIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• Anti-Lox_l_10F9H-LV-hIgG4H-C (SEQ ID NO: 112):
• Anti-Lox_l_10F9H-LV-hIgG4H-C (SEQ ID NO: 113):
• Anti-Lox_l_10F9K-LV-hIgGK-C (SEQ ID NO: 114):
• Anti-Lox_l_10F9K-LV-hIgGK-C (SEQ ID NO: 115):
• Anti-LOX-11 lC8H-LV-hIgG4H-C (SEQ ID NO: 117):
• Anti-LOX-11 lC8K-LV-hIgGK-C (SEQ ID NO: 118):
• Anti-LOX-115C4K-LV-hIgGK-C (SEQ ID NO: 122):
• Anti-LOX-115C4K-LV-hIgGK-C (SEQ ID NO: 123):
• Anti-Marco_10B7.3G4H-LV-hIgG4H-C (SEQ ID NO: 125):
• Anti-Marco_l lA8.3C9_H-V-hIgG4H-C SEQ ID NO: 128,:
• Anti-Marco_l lA8.3C9_H-V-hIgG4H-C SEQ ID NO: 129):
• Anti-Marco_l lA8.3C9_H-V-hIgGK-C SEQ ID NO: 130:
• the antigens of the present invention comprises one or more viral antigens or peptides from adenovirus, retrovirus, picornavirus, herpesvirus, rotaviruses, hantaviruses, coronavirus, togavirus, flavirvirus, rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, reovirus, papilomavirus, parvovirus, poxvirus, hepadnavirus, or spongiform virus, HIV, CMV, hepatitis A, B, and C, influenza; measles, polio, smallpox, rubella; respiratory syncytial, herpes simplex, varicella zoster, Epstein-Barr, Japanese encephalitis, rabies, flu, or cold viruses.
• the antigen is selected from: Nef (66-97): VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL (SEQ ID NO: 136); Nef (116-145): HTQGYFPDWQNYTPGPGVRYPLTFGWLYKL (SEQ ID NO: 137); Gag pl7 (17-35): EKIRLRPGGKKKYKLKHIV (SEQ ID NO: 138); Gag pl7-p24 (253-284): NPPIPVGEIYKRWIILGLNKIVRMYSPTSILD (SEQ ID NO: 139); and/or Pol 325-355 (RT 158- 188) is: AIFQSSMTKILEPFRKQNPDIVIYQYMDDLY (SEQ ID NO: 140).
• the said antigen is 19 to 32 residues and is selected from a cytotoxic T lymphocyte (CTL) epitope identified in the HIV-1 Nef, Gag and Env proteins presented in the context of MHC-class I molecules.
• CTL cytotoxic T lymphocyte
• the Ag is selected from HIV gpl20, gp41, Gag, pl7, p24, p2, p7, pi, p6, Tat, Rev, PR, RT, IN, Vif, Vpr, Vpx, Vpu and Nef.
• the antigen is selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC -related protein (Mucin) (MUC-1, MUC -2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin Bl, cyclin D, Pmel 17(gpl00), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), ⁇ -catenin, MUM-l-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10, C-ERB2 (Her2/
• the Ag is selected from tumor associated antigens comprising antigens from leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia.
• neurological tumors such as astrocytomas or glioblastomas,
• the Ag is selected from at least one of:
• the Ag is selected from at least one of:
• IMDQVPFSV (SEQ ID NO: 146);
• ITDQVPFSV (SEQ ID NO: 147);
• the Ag is selected from at least one of: MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO: 156); and DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO: 157).
• the Ag is selected from at least one of: MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO: 158);
• the Ag is 19 to 32 amino acids long. In another aspect, the Ag is 17 to 60 amino acids long and is selected from a cytotoxic T lymphocyte (CTL) epitope identified in PSA or cyclin 1
• CTL cytotoxic T lymphocyte
• the cancer peptides are selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC -related protein (Mucin) (MUC-1, MUC -2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin Bl, cyclin D, Pmel 17(gpl00), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), ⁇ -catenin, MUM-l-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10, C-ERB
• PBMCs were purified from apheresis blood samples and used after cryopreservation.
• Monocyte-derived IFNa-DCs were prepared from frozen human monocytes (elutriation fraction 5, Lemarie et al, J. Immunological Methods, 2007) cultured with GM-CSF (100 ng/ml) and IFNa (500 U/ml)) (Salluto et al, J. Exp. Med) for 3 days in Cellgenix.
• PBMCs or monocyte-derived IFNa-DCs (2 x 106 cells/ml, 200 ⁇ /well) were cultured in cRPMI containing 10 % human AB serum, 2 mM L-glutamine, 50 U penicillin, 50 ⁇ g/ml streptomycin, 1 X essential amino acids, 25 mM hepes, 55 ⁇ 2-mercapto- ethanol with DC-targeting vaccines and TLR ligands of interest or left unstimulated (negative control) for 24 h, at 37 °C and 5 % C02. Then culture supernatants were harvested and then the secreted cytokines were measured in the culture supernatants using BioPlex200 Luminex (BioRad).
• FIGS. 1A to ID shows flagellin and the several antibody-flagellin contracts of the present invention.
• FIG. 2 shows the design of the studies used to test the activity of the antibody-flagellin constructs of the present invention.
• FIGS. 3A to 3C show the secretion of IL-6 when various types of cells were activated with the construction of the present invention.
• the various cells were IFNalpha activated DCs and Peripheral Blood Mononuclear Cells (PBMCs).
• FIGS. 4A to 4B show the dose titration of the various constructs as measured by the secretion of IL-6 and IL-1 beta.
• the flagellin activity is dependent on the targeting antibody and is effective even at the lowest 0.1 nM dose, while the isotype control gives only a response at 25 nM dose.
• FIG. 4C and 4D show the dose titration of the various constructs as measured by the secretion of IL-6 and IL-1 beta.
• the flagellin activity is dependent on the targeting antibody and is effective even at the lowest 0.1 nM dose, while the isotype control gives only a response at 25 nM dose.
• the addition of free antibody to the isotype control does not restore the flagellin activity.
• FIG. 5 shows heat maps of gene expression for the listed genes using an anti-LOX-1 antibody with or without flagellin.
• compositions of the invention can be used to achieve methods of the invention.
• the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), "including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
• A, B, C, or combinations thereof refers to all permutations and combinations of the listed items preceding the term.
• A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB.
• expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth.
• the skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
• compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it may be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
• U.S. Patent Application Publication No. 20080220011 Use ofFlagellin in Tumor Immunotherapy.
• U.S. Patent Application Publication No. 20080248068 Use ofFlagellin as an Adjuvant for Vaccine.
• U.S. Patent No. 7,404,963 Flagellin-Based Adjuvants and Vaccines.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Tropical Medicine & Parasitology (AREA)
• Virology (AREA)
• Pulmonology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=45564978

Family Applications (1)

Country Status (14)

Cited By (17)

Families Citing this family (39)

Citations (2)

Family Cites Families (11)

• 2011
  • 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
  • 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
  • 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
  • 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
  • 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
  • 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
  • 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
  • 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
  • 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
  • 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
  • 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
  • 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
  • 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
• 2013
  • 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events